The fentanyl crisis is a public health emergency driven by the spread of illicitly manufactured fentanyl, a synthetic opioid roughly 100 times more potent than morphine and 50 times more potent than heroin. In the 12 months ending November 2025, over 70,000 Americans died from drug overdoses, with synthetic opioids like fentanyl responsible for the majority. A lethal dose fits on the tip of a pencil, making it uniquely dangerous both for people who use drugs intentionally and for those who encounter it unknowingly in counterfeit pills or mixed into other substances.
Why Fentanyl Is So Dangerous
Fentanyl works by binding powerfully to the same receptors in the brain that all opioids target. What sets it apart is how efficiently it suppresses breathing. Within seconds of entering the bloodstream, fentanyl slows both the rate and depth of each breath. It reduces the force of inhalation, delays exhalation, and destabilizes the normal rhythm of breathing, sometimes causing repeated pauses (apneas) and disordered breathing patterns. In animal studies, a single injection caused immediate drops in breathing frequency, the volume of each breath, and overall air movement through the lungs.
This is the mechanism behind most fentanyl deaths: the brain’s drive to breathe weakens until it stops altogether. Because the drug is so potent by weight, the difference between a dose that produces a high and one that kills can be measured in fractions of a milligram. That razor-thin margin means small errors in dosing, whether by a user or a drug supplier, can be fatal.
Where It Comes From
The fentanyl flooding U.S. streets is not diverted from pharmacies or hospitals. It is synthesized in clandestine labs, primarily in Mexico, by transnational criminal organizations. The raw ingredients, known as precursor chemicals, originate overwhelmingly from China. The U.S. intelligence community’s March 2025 Annual Threat Assessment identified China as “the primary source country for illicit fentanyl precursor chemicals and pill pressing equipment.” China’s massive chemical and pharmaceutical industries make it a natural hub for these sales, and the same supply chains feed production of other illicit drugs including methamphetamine and ketamine.
Once precursors reach Mexico, criminal organizations synthesize fentanyl and press it into counterfeit pills designed to look like legitimate prescription medications, or package it as powder. These products then cross the U.S. border through established smuggling routes. The entire pipeline, from chemical factory to street sale, can operate with relatively small physical volumes because fentanyl’s extreme potency means a kilogram of product goes much further than a kilogram of heroin.
A Contaminated Drug Supply
One of the crisis’s most alarming features is that fentanyl has infiltrated the supply of nearly every other street drug. People buying what they believe is heroin, cocaine, or prescription painkillers may be consuming fentanyl without knowing it. Counterfeit pills stamped to look like oxycodone or Xanax frequently contain fentanyl in unpredictable amounts.
The problem has grown worse with the addition of xylazine, an animal tranquilizer sometimes called “tranq” or “tranq dope.” Xylazine is not an opioid and is not approved for human use, but drug suppliers mix it into fentanyl to enhance sedation or simply to increase the weight of their product. The DEA has seized fentanyl-xylazine mixtures in 48 of 50 states. Roughly 23% of fentanyl powder and 7% of fentanyl pills seized by the DEA in 2022 contained xylazine.
Xylazine creates additional dangers that standard overdose treatments can’t address. Because it’s not an opioid, naloxone (the medication used to reverse opioid overdoses) does not counteract its effects. People exposed to xylazine can develop dangerously low blood pressure, slowed heart rate, and severe difficulty breathing on top of fentanyl’s own respiratory suppression. Chronic xylazine use also causes distinctive skin wounds that worsen quickly and can lead to serious infections or amputation if untreated. In Philadelphia, xylazine appeared in 31% of overdose deaths involving heroin or fentanyl in 2019, and the percentage of fentanyl-related deaths nationally involving xylazine rose from 3% in January 2019 to 11% by mid-2022.
Who Is Most Affected
The crisis hits some communities harder than others. In 2024, the highest opioid overdose death rates were among adults aged 26 to 44 (29.1 per 100,000) and 45 to 64 (24.9 per 100,000). These working-age adults bear the heaviest burden, though no age group is untouched. Adults 65 and older saw their rates climb 63% compared to 2019, the steepest relative increase of any age group even as overall deaths began declining.
Racial disparities are stark. American Indian and Alaska Native people had the highest opioid death rate in 2024 at 35.5 per 100,000, a figure that has more than doubled since 2019. Black Americans died at a rate of 22.8 per 100,000, notably higher than the white rate of 17.5. These gaps reflect broader inequities in healthcare access, economic stability, and the availability of treatment and harm reduction services.
Geography matters too. State-level death rates in 2024 ranged from 3.3 per 100,000 in Nebraska to 38.6 per 100,000 in West Virginia. Alaska (37.0) and the District of Columbia (34.1) also ranked among the worst-hit areas. Some states that historically had lower overdose rates have seen explosive growth: Alaska and Oregon experienced increases of 239% and 226% respectively compared to 2019.
Recent Trends: A Partial Improvement
After years of relentless escalation, opioid overdose deaths began declining in 2023 and continued to fall through 2024. Death rates dropped across every demographic group and every state. Young adults aged 18 to 25 saw the largest decline at 42%. Some of the hardest-hit states experienced dramatic improvements: West Virginia’s rate fell 46%, and Virginia and Wisconsin each dropped 44%.
These declines likely reflect a combination of factors, including wider availability of naloxone, expanded access to medications that treat opioid addiction, increased fentanyl test strip distribution, and some disruption of supply chains. But the improvements should be read cautiously. The overall death toll remains far above pre-crisis levels, and certain populations, particularly older adults and Native Americans, remain deeply affected. A crisis that kills roughly 70,000 Americans a year has not ended because the trend line bent downward.
The Policy Response
The federal government has pursued both supply-side enforcement and diplomatic pressure. Fentanyl and its known analogues are classified as Schedule II controlled substances, carrying severe criminal penalties. Congress has pushed to extend those penalties to cover the constantly evolving array of fentanyl-related substances that chemists tweak to evade existing law. The HALT Fentanyl Act, introduced in the 119th Congress, would permanently place fentanyl-related substances under the same penalties as fentanyl analogues, closing a gap that allowed novel variations to exist in a legal gray area.
On the international front, U.S. officials have pressured China to regulate precursor chemical exports more tightly. China has taken some steps, including scheduling certain precursors, but enforcement remains inconsistent given the sheer scale of China’s chemical industry. The production of U.S.-bound fentanyl remains concentrated in Mexico, where criminal organizations operate with significant resources and territorial control.
At the state and local level, responses vary widely. Some jurisdictions have invested heavily in harm reduction, distributing naloxone and fentanyl test strips and opening supervised consumption sites. Others have focused primarily on law enforcement. The patchwork nature of these responses helps explain why outcomes differ so dramatically from state to state, with death rates varying more than tenfold across the country.